Company intelligence / Profile preview

Ohemo Life

Suzhou, Jiangsu, China

Ownership: Private
Employees: ~50
Development stage: Other

Overview

Ohemo Life is a clinical-stage biotechnology company dedicated to developing next-generation small molecule precision medicines for oncology and hematology. Based in Suzhou, China, the company focuses on targeting critical nodes in oncogenic signaling pathways, particularly the RAS/MAPK pathway, which are often considered undruggable. Its lead program, OHM-001, is a highly selective SHP2 inhibitor currently undergoing Phase 1 clinical trials for the treatment of advanced solid tumors. Ohemo Life's pipeline also includes inhibitors targeting KRAS G12C and SOS1, aimed at providing synergistic combination therapies. The company is supported by top-tier venture capital firms such as Lilly Asia Ventures and Qiming Venture Partners.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Ohemo Life.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ohemo Life.

Explore the full profile